SANTÉ

We’re excited to see encouraging new data from Geneos Therapeutics highlighted recently by Inside Precision Medicine. The company’s personalized DNA vaccine approach demonstrated promising immune activation and survival signals in glioblastoma, which is one of the most aggressive and difficult-to-treat forms of cancer. This work reflects the potential of truly individualized immunotherapy platforms to unlock new treatment possibilities for patients with significant unmet medical needs. We’re proud to support the Geneos team as they continue advancing precision immunotherapies designed to improve outcomes in oncology! https://lnkd.in/gnzuFk8B

We’re excited to see Iterion Therapeutics present Phase 1/2 data for tegavivint in advanced HCC at the 2026 ASCO Annual Meeting!   The selection of an oral presentation underscores the growing interest in targeting the Wnt/β-catenin pathway, which is one of the most challenging and important areas in oncology. It also highlights the progress Iterion is making in developing novel therapies for patients with limited treatment options.   Congratulations to the entire team on this important milestone. We look forward to following the continued clinical advancement of tegavivint across Wnt-driven cancers.   https://lnkd.in/eRvjXs7X

Strong momentum from Kestrel Therapeutics! The first patient has been dosed in the Phase 1 trial of KST-6051, and this came alongside a strategic partnership with AbbVie that includes a potential path to acquisition.   The milestone reflects both clinical progress and external validation of Kestrel’s approach to targeting KRAS, one of the most common drivers of cancer. KST-6051 is being evaluated in patients with advanced KRAS-driven tumors, including pancreatic, colorectal, and lung cancers, with the goal of addressing a broader range over time.   We’re proud to support the Kestrel team as they advance a next-generation approach to KRAS, and to see that progress recognized through both clinical execution and strategic interest. Looking forward to continued momentum ahead.   https://lnkd.in/debE9-4Q

We’re proud to lead the $18M Series A round for SONIRE Therapeutics Inc. as they advance a new approach to treating pancreatic cancer – which is among the most deadly and hardest to treat.   Sonire has developed a next-generation high-intensity focused ultrasound (HIFU) platform that delivers precise, non-invasive tumor ablation. Patients do not need anesthesia and treatment can be completed in an outpatient setting.   The funding will support completion of the world’s first randomized HIFU trial in pancreatic cancer, and accelerate U.S. clinical development following the company’s FDA Breakthrough Device Designation. With pancreatic cancer still facing significant unmet need, innovations that can improve outcomes while reducing treatment burden are critical. Sonire’s technology has the potential to reshape how these patients are treated.   Congratulations to the Sonire team on this important milestone!   https://lnkd.in/e-SE9qqk

We’re honored to be featured as the cover story in the latest issue of LSI’s The Lens.   The piece highlights our continued focus on early-stage investing across #medtech, #healthtech, and #biotech, and the conviction we think is required to back transformative ideas long before they are widely recognized.   With the close of our $330M Fund V, we remain committed to partnering with founders at the earliest stages, where innovation is highest and outcomes can meaningfully reshape patient care.   As the venture landscape evolves, our approach remains consistent: disciplined investing, deep domain expertise, and a long-term view on building category-defining companies.   https://lnkd.in/gwqT3wfX

Always happy to share exciting news from our portfolio companies! And this week, ABK Biomedical Inc. has just announced a long-term partnership with the University of Missouri Research Reactor - MURR® to advance its next-generation radiotherapeutic platform.   The collaboration strengthens a critical link between isotope production and clinical application, supporting the development of ABK’s Eye90 microspheres. This is a targeted Y-90 therapy that is designed to improve precision and visualization in the treatment of liver tumors.   By integrating manufacturing capabilities with translational research infrastructure, this partnership is intended to accelerate the path from development to clinical use, expanding access to novel radiopharmaceutical approaches in oncology.   We believe innovations at the intersection of device engineering, imaging, and targeted radiation will continue to play an important role in improving outcomes for patients with difficult-to-treat cancers. Looking forward to the next phase of progress from the ABK team and their collaborators!   https://lnkd.in/gNDvCac3

Big news from Endogenex! The team has announced $50M in new financing to advance its minimally invasive, endoscopic approach to treating Type 2 diabetes, alongside FDA clearance to move the program forward.   By targeting the underlying metabolic dysfunction through a novel intestinal intervention, Endogenex is working toward a potential shift from chronic disease management to disease modification. This progress reflects both strong clinical validation to date and growing interest in alternatives that complement or extend beyond GLP-1 therapies.   We’re proud to support the Endogenex team as they advance a differentiated approach to one of the most significant global health challenges.   https://lnkd.in/gBCiK8MP

Encouraged to see continued momentum from Iterion Therapeutics as they advance the clinical development of tegavivint.   The company announced that the first patient has been dosed in a study expanding this first-in-class Wnt/β-catenin inhibitor into colorectal cancer, which is an important step in exploring its potential across additional Wnt-driven tumors.   Tegavivint targets a pathway long considered difficult to drug, with broad implications across multiple cancer types where Wnt/β-catenin signaling plays a central role in tumor growth and progression.   We’re proud to support Iterion as they work to translate this novel mechanism into meaningful outcomes for patients!   https://lnkd.in/gb5k29zV

Great thoughts from Omar H. Khalil, who recently sat down with Michael Gibney of PharmaVoice to share his perspective on the evolving #biotech venture landscape. In short, cautious optimism could be seeing a return to the sector.   After several challenging years marked by inflated valuations, rising development costs, and constrained capital, we’re now seeing early signs of a reset. Additionally, public market dynamics are beginning to support private biotech financing.   At the same time, the bar has been raised. Today’s environment is increasingly defined by:   A renewed focus on clinical data and differentiation More efficient, capital-conscious company building Greater alignment between biotech innovation and pharma demand   As Omar notes, this cycle has produced a stronger, more resilient cohort of companies, which are positioned to deliver meaningful impact for patients and the broader healthcare system.   https://lnkd.in/eSrn8i8V

Big week ahead at LSI USA '26!   At SANTÉ, we’re proud to have both Auriel August, MD and Ashley Seehusen on stage this week at the Waldorf Astoria, sharing practical insights on raising capital and building the next generation of healthcare companies.   Here are the sessions we will be active in this week:   Day 1 - Tuesday March 17th   12:00, Auriel will join the discussion on “Differentiating Your Pitch to Win Early-Stage Capital”   Day 2 – Wednesday March 18th   12:15, Ashley will share thoughts on decoding investor expectations 12:45, Auriel will join another discussion on building the future of healthcare   Day 3 – Thursday March 19th   12:45, Ashley will also join The Intentional Pipeline: Building Next-Generation Medtech from the Ground Up   If you’re attending LSI, come say hello! We’d love to connect with fellow founders, investors, and innovators shaping the future of healthcare.   See you in Monarch Beach!   #LSIUSA2026   https://lnkd.in/e5hXHh97